Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Phase 2

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: Everolimus Placebo

First Posted Date: 2017-10-18

Last Posted Date: 2024-01-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 159

Registration Number: NCT03312738

Locations: 🇨🇳
Novartis Investigative Site, Wuhan, China

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: LHC165
Biological: PDR001

First Posted Date: 2017-10-04

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT03301896

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients

Phase 4

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsatran
Drug: valsartan
Drug: placebo to valsartan
Drug: placebo to sacubitril/valsartan

First Posted Date: 2017-10-03

Last Posted Date: 2024-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT03300427

Locations: 🇫🇮
Novartis Investigative Site, Turku, Finland

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Other: Placebo to CJM112
Drug: CJM112

First Posted Date: 2017-10-03

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT03299686

Locations: 🇸🇰
Novartis Investigative Site, Spisska Nova Ves, Slovakia

Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)

Phase 2

Terminated

Conditions: Painful Diabetic Neuropathy

Interventions: Drug: EMA401
Drug: Placebo

First Posted Date: 2017-09-29

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT03297294

Locations: 🇬🇧
Novartis Investigative Site, Oldham, United Kingdom

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Phase 2

Terminated

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: VAY736
Drug: Standard of Care (SoC)

First Posted Date: 2017-09-19

Last Posted Date: 2024-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT03287414

Locations: 🇬🇧
Novartis Investigative Site, High Heaton, Newcastle Upon Tyne, United Kingdom

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Midostaurin
Drug: Placebo

First Posted Date: 2017-09-12

Last Posted Date: 2025-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 67

Registration Number: NCT03280030

Locations: 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam

Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Other: Placebo
Biological: LNA043

First Posted Date: 2017-09-07

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 142

Registration Number: NCT03275064

Locations: 🇩🇰
Novartis Investigative Site, Hvidovre, Denmark

Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)

Phase 2

Completed

Conditions: Sickle Cell Disease (SCD)

Interventions: Drug: crizanlizumab

First Posted Date: 2017-08-29

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT03264989

Locations: 🇺🇸
Childrens Healthcare of Atlanta ., Atlanta, Georgia, United States
🇺🇸
University of Maryland Medical Ctr, Baltimore, Maryland, United States
🇺🇸
East Carolina University East Carolina University, Greenville, North Carolina, United States

and more 8 locations

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: AIN457 150 mg
Biological: Placebo
Biological: GP2017 (adalimumab biosimilar)

First Posted Date: 2017-08-23

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 859

Registration Number: NCT03259074

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy